Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Italy / NCT05839392
Recruiting Not applicable

Novel Approaches to Target MECOM/EVI1 in AML

NCT05839392 · tracked via the Priya Life Science Italy tracker
Sponsor
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase
Not applicable
Started
2023-12-13
Last updated
2023-12-29

Condition(s) studied

AML, Adult

Investigational drug(s) / intervention(s)

Biological characterization of AML with MECOM or atypical 3q26 rearrangements

Biological characterization of AML with MECOM or atypical 3q26 rearrangements: Peripheral blood and bone marrow withdrawal

Study summary

This is an academic, no-profit, multicenter, biological, non-pharmacologic study aimed at characterizing genome, transcriptome and proteome of patients affected by AML with MECOM or atypical 3q26 rearrangements.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * AML with MECOM or atypical 3q26 rearrangements. * Age ≥18. * Signed written informed consent according to ICH/EU/GCP and national local laws. Exclusion Criteria: * None

Primary outcome measure(s)

  • Identification of MECOM/EVI1 regulators or downstream effectors potentially druggable — At baseline
    To assess the number of regulators or effectors of MECOM/EVI1

Trial sites (1)

FacilityCityRegionStatus
Ematologia Piacenza Italy Recruiting

More Gruppo Italiano Malattie EMatologiche dell'Adulto trials in Italy

Gemtuzumab Chemotherapy MRD Levels; Adult Untreated, de Novo, Fav Interm Risk AML Recruiting
Observational Study on the Outcome of AML Patients Treated With New Drugs in Real-life (BoxTrial) Recruiting
Front-line VenObi Combination Followed by Ven or VenZan Combination in Patients With Residual Disease: a MRD Tailored Treatment for Young Patients With High-risk CLL Active, not recruiting
Trial in AML Secondary to MPNs Patients, Unfit for Intensive Chemotherapy, Investigating a Treatment Combination Including Decitabine and Venetoclax Active, not recruiting
Molecular Mechanisms of Disease Relapse After Allogenic Stem Cell Transplantation in MDS Patients Recruiting

Other trials for the same condition

Observational Study on the Outcome of AML Patients Treated With New Drugs in Real-life (BoxTrial) Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05839392 on ClinicalTrials.gov ↗ ← All trials in Italy